Navigation Links
Anadys Highlights ANA773 Data to be Presented at ASCO
Date:5/25/2011

SAN DIEGO, May 25, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company focused on developing medicines for the treatment of hepatitis C, announced today that it will present data from a previously conducted cancer study of ANA773, the Company's oral immuno-modulator that acts via the TLR-7 pathway, at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.  The data from the completed Phase I study is being presented on June 4, 2011 in a poster titled "Phase I Open Label, Dose Escalation Study of ANA773 Tosylate, an Oral Prodrug of a Toll-Like Receptor-7 Agonist, in Patients with Advanced Solid Tumors".  The poster will be available on the Company's website at www.anadyspharma.com as of the date of presentation.  

In the Phase I cancer study, ANA773 showed a favorable safety and tolerability profile at doses that had desired effects on the innate immune system.  A confirmed partial response was achieved in a patient with melanoma and prolonged stable disease was observed in additional patients.  A maximum tolerated dose (MTD) was not reached in this study.  These results suggest that ANA773 may provide clinical benefit to cancer patients.  

"The clinical activity seen with ANA773 in this Phase I oncology study is quite promising," said James L. Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer.  "While Anadys is focusing its development efforts in the area of hepatitis C, we continue to believe that ANA773 holds promise for the treatment of a range of cancer types, particularly in combination with other agents such as monoclonal antibodies that rely on immune mechanisms for activity."  

About the Concluded Phase I study of ANA773 in Cancer

Patients with
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
3. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
5. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
6. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
10. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
11. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... The new research report, “Gas Insulated Switchgear (GIS) ... & Secondary), and End-User (Transmission & Distribution, Manufacturing ... - Trends and Forecasts to 2019”, defines and ... of the market size. , Browse more than ... through 146 Pages and in-depth TOC on “Gas ...
(Date:10/27/2014)... Mass. and TORONTO ... Corporation ( www.generex.com ) (OTCQB: GNBT) today announced ... immunological response triggered by its novel proprietary cancer ... relapse in breast cancer patients. The AE37 cancer ... subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). The ...
(Date:10/27/2014)... The “Molecular Diagnostic Market ... (PCR, INAAT, DNA Sequencing), End User (Hospital, Laboratories), ... Global Forecast to 2018” provides a detailed overview ... market trends, and strategies impacting the global molecular ... of the revenue and share analysis. , The ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 Called ... reducing and eliminating several types of pediatric brain ... been achieved in over 30 years of research ... Light Foundation, proves that one mom's determination can ... just before Halloween trick-or-treating, and it’s only fitting ...
Breaking Biology Technology:Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3
... BioTechnologies, Inc. (TriLink) and Lucigen Corporation (Lucigen) announced today ... for the use of TriLink,s CleanAmp™ dNTPs in Lucigen,s ... CleanAmp™ dNTPs are an innovative approach to Hot Start ... PCR assay with CleanAmp™ dNTPs, a Hot Start reaction ...
... DIEGO, July 28, 2011 Verenium Corporation (NASDAQ: ... commercialization of high-performance industrial enzyme solutions, today announced that ... its 5.5% Notes and approximately $3 million in principal ... very pleased to have taken another important step toward ...
... July 28, 2011 United Therapeutics Corporation (NASDAQ: ... ended June 30, 2011. "I,m pleased with the ... as the very good operating results we achieved," remarked Martine ... remain on track to reach our 2011 forecast for revenues ...
Cached Biology Technology:TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation 2Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 7
(Date:10/28/2014)... National University of Singapore (NUS) have discovered a new ... laying direct developing eggs in live bamboo with narrow ... bush frog ( Raorchestes chalazodes ). This critically ... known to adopt this novel reproductive strategy. The findings ... Biological Journal of the Linnean Society , in October ...
(Date:10/28/2014)... juices are associated with a lower risk of developing ... of East Anglia (UEA). , Research published today ... flavanones (both subclasses of dietary flavonoids) significantly decrease their ... of cancer death among women. , The research ... between 25 and 55 for more than three decades. ...
(Date:10/27/2014)... German . ... via electrical signals, they communicate with each other at ... substances, the neurotransmitters, are stored in vesicles at the ... vesicles fuse with the cell membrane and release their ... synapses always have some readily releasable vesicles on standby. ...
Breaking Biology News(10 mins):NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2Synapses always on the starting blocks 2Synapses always on the starting blocks 3
... they know to fear the scent of a predator. But how ... cat is nearby? It,s a complex process that starts ... noses. But until now it wasn,t clear exactly how these scent ... a study to be published in Nature (available online ...
... is relatively common to come across petrol stations surrounded by ... Murcia (UM) have studied the effects of contamination at petrol ... noted in buildings less than 100 metres from the service ... which increases the risk of cancer have been recorded ...
... It,s the champagne of the cheese world and the ... like Stilton are literally under the microscope in a quest ... of Nottingham and The University of Northampton are working with ... distinctive taste, texture and smell. The scientists hope to ...
Cached Biology News:The brain knows what the nose smells, but how? Stanford researchers trace the answer 2The brain knows what the nose smells, but how? Stanford researchers trace the answer 3Petrol stations pollute their immediate surroundings 2The quest for the ultimate blue cheese 2
Edited by Benjamin Lewin (1997) • This book gives an integrated account of the structure and function of genes in both prokaryotic organisms and is thoroughly up to date with the latest thinking...
... TOPO Cloning is the ... for cloning PCR products. ... Zero Blunt TOPO vectors ... activated with topoisomerase I. ...
...
Applications: ISH...
Biology Products: